These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36084402)

  • 21. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis.
    Dias DS; Ribeiro PAF; Martins VT; Lage DP; Portela ÁSB; Costa LE; Salles BCS; Lima MP; Ramos FF; Santos TTO; Caligiorne RB; Chávez-Fumagalli MA; Silveira JAG; Magalhães-Soares DF; Gonçalves DU; Oliveira JS; Roatt BM; Duarte MC; Menezes-Souza D; Silva ES; Galdino AS; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
    Mol Immunol; 2017 Nov; 91():272-281. PubMed ID: 28988041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.
    Aguiar-Soares RD; Roatt BM; Ker HG; Moreira Nd; Mathias FA; Cardoso JM; Gontijo NF; Bruna-Romero O; Teixeira-Carvalho A; Martins-Filho OA; Corrêa-Oliveira R; Giunchetti RC; Reis AB
    Parasit Vectors; 2014 Feb; 7():61. PubMed ID: 24507702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis.
    de Oliveira Emerick S; Vieira de Carvalho T; Meirelles Miranda B; Carneiro da Silva A; Viana Fialho Martins T; Licursi de Oliveira L; de Almeida Marques-da-Silva E
    Vaccine; 2021 Jan; 39(2):282-291. PubMed ID: 33309484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model.
    Carvalho LM; Gusmão MR; Costa AFP; de Brito RCF; Aguiar-Soares RDO; Cardoso JMO; Reis AB; Carneiro CM; Roatt BM
    Parasitology; 2022 Mar; 149(3):371-379. PubMed ID: 35264268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A recombinant chimeric protein composed of human and mice-specific CD4
    Martins VT; Duarte MC; Lage DP; Costa LE; Carvalho AM; Mendes TA; Roatt BM; Menezes-Souza D; Soto M; Coelho EA
    Parasite Immunol; 2017 Jan; 39(1):. PubMed ID: 27593711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Live attenuated Leishmania infantum centrin deleted mutant (LiCen
    Zarei Z; Mohebali M; Dehghani H; Khamesipour A; Tavakkol-Afshari J; Akhoundi B; Abbaszadeh-Afshar MJ; Alizadeh Z; Eskandari SE; Asl AD; Razmi GR
    Comp Immunol Microbiol Infect Dis; 2023 Jun; 97():101984. PubMed ID: 37119594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.
    Jesus MM; Lage DP; Vale DL; Freitas CS; Pimenta BL; Moreira GJL; Ramos FF; Pereira IAG; Bandeira RS; Ludolf F; Tavares GSV; Galdino AS; Duarte MC; Menezes-Souza D; Chávez-Fumagalli MA; Teixeira AL; Gonçalves DU; Roatt BM; Christodoulides M; Martins VT; Coelho EAF
    Parasitol Res; 2023 Dec; 122(12):2917-2931. PubMed ID: 37768367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoprophylaxis using polypeptide chimera vaccines plus adjuvant system promote Th1 response controlling the spleen parasitism in hamster model of visceral leishmaniasis.
    Gusmão MR; Ostolin TLVDP; Carvalho LM; Costa AFP; Moreira GJL; Cardoso JMO; Aguiar-Soares RDO; Reis AB; de Brito RCF; Roatt BM
    Vaccine; 2022 Sep; 40(37):5494-5503. PubMed ID: 35963820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
    Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
    Front Immunol; 2018; 9():465. PubMed ID: 29599776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.
    Roatt BM; Aguiar-Soares RD; Vitoriano-Souza J; Coura-Vital W; Braga SL; Corrêa-Oliveira R; Martins-Filho OA; Teixeira-Carvalho A; de Lana M; Figueiredo Gontijo N; Marques MJ; Giunchetti RC; Reis AB
    PLoS One; 2012; 7(11):e49780. PubMed ID: 23189161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of prime and prime-boost immunization strategies in BALB/c mice inoculated with Leishmania infantum transfected with toxic plasmids.
    Augusto Sanches Roque G; Esteves Zorgi N; Janaína Soares Rocha F; Flóro E Silva M; Fernanda Araújo T; Ruiz Abánades D; Giorgio S
    Vaccine; 2022 Jul; 40(31):4105-4115. PubMed ID: 35660330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis.
    Oliveira-da-Silva JA; Lage DP; Ramos FF; Machado AS; Tavares GSV; Mendonça DVC; Pereira IAG; Martins VT; Carvalho LM; Ludolf F; Santos TTO; Reis TAR; Oliveira CS; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Menezes-Souza D; Roatt BM; Teixeira AL; Coelho EAF
    Mol Immunol; 2020 Aug; 124():161-171. PubMed ID: 32585510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probing the efficacy of a heterologous Leishmania/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice.
    Santos TTO; Martins VT; Lage DP; Costa LE; Salles BCS; Carvalho AMRS; Dias DS; Ribeiro PAF; Chávez-Fumagalli MA; Machado-de-Ávila RA; Roatt BM; de Magalhães-Soares DF; Menezes-Souza D; Coelho EAF; Duarte MC
    Acta Trop; 2017 Jul; 171():8-16. PubMed ID: 28288798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.